Friday, May 20, 2011
Repligen Corp., of Waltham, Mass., received approval from the FDA to initiate a Phase I trial of RG3039, a potential treatment for spinal muscular atrophy, an inherited neurodegenerative disease. The company said the double-blind study will evaluate the pharmacokinetic and safety profile of escalating doses of RG3039 in as many as 40 healthy volunteers.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.